Formulation of liposomes functionalized with Lotus lectin and effective in targeting highly proliferative cells

Giovampaola, Cristian Della; Capone, Antonietta; Ermini, Leonardo; Lupetti, Pietro; Vannuccini, E.; Finetti, Federica; Donnini, Sandra; Ziche, Marina; Magnani, Agnese; Leone, Gemma; Rossi, Claudio; Rosati, Floriana; Bonechi, Claudia

doi:10.1016/j.bbagen.2017.01.015

Cited by 31 publications

(9 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have been conducted using NPs functionalized with carbohydrate-recognizing lectins [ 129 , 130 , 131 , 132 , 133 ]. For instance, the mannose-binding concanavalin A was used to functionalize NPs and target sialic acids [ 129 , 133 ].…”

Section: Sweetening Precision Oncology With Glycan-directed Nanoparti...mentioning

confidence: 99%

“…In addition, the conjugation of the wheat germ agglutinin to NPs loaded with anti-tumor chemotherapeutics has been shown to significantly enhance cancer cell-specific uptake, while minimizing off-target cytotoxicity [ 130 ]. Similar strategies have been employed for the targeting of cancer cells enriched in fucosylated antigens, such as Lewis x (Le x ), using the fucose-recognizing lectins aleuria aurantia lectin [ 131 ] and the lotus tetragonolobus lectin [ 132 ].…”

Section: Sweetening Precision Oncology With Glycan-directed Nanoparti...mentioning

confidence: 99%

See 1 more Smart Citation

Glycans as Targets for Drug Delivery in Cancer

Diniz

Coelho

Duarte

et al. 2022

Cancers

View full text Add to dashboard Cite

Innovative strategies have been proposed to increase drug delivery to the tumor site and avoid cytotoxicity, improving the therapeutic efficacy of well-established anti-cancer drugs. Alterations in normal glycosylation processes are frequently observed in cancer cells and the resulting cell surface aberrant glycans can be used as direct molecular targets for drug delivery. In the present review, we address the development of strategies, such as monoclonal antibodies, antibody–drug conjugates and nanoparticles that specific and selectively target cancer-associated glycans in tumor cells. The use of nanoparticles for drug delivery encompasses novel applications in cancer therapy, including vaccines encapsulated in synthetic nanoparticles and specific nanoparticles that target glycoproteins or glycan-binding proteins. Here, we highlight their potential to enhance targeting approaches and to optimize the delivery of clinically approved drugs to the tumor microenvironment, paving the way for improved personalized treatment approaches with major potential importance for the pharmaceutical and clinical sectors.

show abstract

Section: Sweetening Precision Oncology With Glycan-directed Nanoparti...mentioning

confidence: 99%

Section: Sweetening Precision Oncology With Glycan-directed Nanoparti...mentioning

confidence: 99%

Glycans as Targets for Drug Delivery in Cancer

Diniz

Coelho

Duarte

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Cisplatin encapsulated in ferritin nanoparticles, decorated with a melanoma-targeting antibody (Ep-1), also showed good in vivo anticancer activity following intravenous (iv) injection in mice bearing Colo 38 human melanoma cells tumors [242]. Other strategies, including lectin targeted dioleoylphosphatidylcholine (DOPC)/dioleoylphosphatidylethanolamine (DOPE) liposomes [255], PEGylated poly (εcaprolactone) nanoparticles [256] and PEGylated gold nanoparticles targeted with RGD-like peptide [150], showed good ability to accumulate at the tumor site.…”

Section: Pre-clinical Development Of Nanomedicines For Melanoma Therapy In Italymentioning

confidence: 99%

Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape

et al. 2021

View full text Add to dashboard Cite

Cutaneous melanoma is one of the most aggressive solid tumors, with a low survival for the metastatic stage. Currently, clinical melanoma treatments include surgery, chemotherapy, targeted therapy, immunotherapy and radiotherapy. Of note, innovative therapeutic regimens concern the administration of multitarget drugs in tandem, in order to improve therapeutic efficacy. However, also, if this drug combination is clinically relevant, the patient’s response is not yet optimal. In this scenario, nanotechnology-based delivery systems can play a crucial role in the clinical treatment of advanced melanoma. In fact, their nano-features enable targeted drug delivery at a cellular level by overcoming biological barriers. Various nanomedicines have been proposed for the treatment of cutaneous melanoma, and a relevant number of them are undergoing clinical trials. In Italy, researchers are focusing on the pharmaceutical development of nanoformulations for malignant melanoma therapy. The present review reports an overview of the main melanoma-addressed nanomedicines currently under study in Italy, alongside the state of the art of melanoma therapy. Moreover, the latest Italian advances concerning the pre-clinical evaluation of nanomedicines for melanoma are described.

show abstract

“…In order to evaluate this hypothesis, preliminary studies were performed by using unilamellar liposomes as simplied models of cell membranes. Liposomes were synthesized with 1,2-dioleoyl-sn-glycerophosphocholine (DOPC) and 1,2-dioleoyl-sn-glycerophosphoethanolamine (DOPE), which are commonly used in zwitterionic liposomes, 38,39 since they form a uid bilayer at room temperature. Furthermore, the phosphocholine and phosphoethanolamine are the most abundant polar head types in the outer cell membrane.…”

Section: Dynamic Light Scattering (Dls) Characterization Of Ha-fa-negmentioning

confidence: 99%